179 related articles for article (PubMed ID: 9919333)
1. Single agent paclitaxel in resistant and relapsed epithelial ovarian cancer after first-line platinum-based chemotherapy--experience in an Asian population.
Tay SK; Thilagam MD
Ann Acad Med Singap; 1998 Sep; 27(5):645-9. PubMed ID: 9919333
[TBL] [Abstract][Full Text] [Related]
2. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
Gynecol Oncol; 2000 Nov; 79(2):211-5. PubMed ID: 11063646
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
5. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma.
Dunder I; Berker B; Atabekoglu C; Bilgin T
Eur J Gynaecol Oncol; 2005; 26(1):79-82. PubMed ID: 15755007
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.
Gore ME; Levy V; Rustin G; Perren T; Calvert AH; Earl H; Thompson JM
Br J Cancer; 1995 Oct; 72(4):1016-9. PubMed ID: 7547214
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
[TBL] [Abstract][Full Text] [Related]
9. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.
Mayerhofer K; Kucera E; Zeisler H; Speiser P; Reinthaller A; Sevelda P
Gynecol Oncol; 1997 Jan; 64(1):109-13. PubMed ID: 8995557
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy.
Blom R; Palm N; Simonsen E
Acta Oncol; 1996; 35(6):733-6. PubMed ID: 8938222
[TBL] [Abstract][Full Text] [Related]
11. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum.
du Bois A; Lück HJ; Buser K; Meerpohl HG; Sessa C; Klaassen U; Meden H; Bochtler H; Diergarten K
Eur J Cancer; 1997 Mar; 33(3):379-84. PubMed ID: 9155520
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Ball H; Hummel SJ; Barrett RJ
J Clin Oncol; 1994 Sep; 12(9):1748-53. PubMed ID: 7916038
[TBL] [Abstract][Full Text] [Related]
13. Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer.
Phillips KA; Friedlander M; Olver I; Evans B; Smith J; Fitzharris B; McCrystal M; Joughin J; Bishop J
Aust N Z J Med; 1995 Aug; 25(4):337-43. PubMed ID: 8540875
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
[TBL] [Abstract][Full Text] [Related]
15. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.
Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C
Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients.
Oliverio G; Canuti D; Tononi A; Scarpellini M; Panzini I; Galli I; Ravaioli A
J Chemother; 1999 Aug; 11(4):301-5. PubMed ID: 10465133
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
19. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group.
Buda A; Floriani I; Rossi R; Colombo N; Torri V; Conte PF; Fossati R; Ravaioli A; Mangioni C
Br J Cancer; 2004 Jun; 90(11):2112-7. PubMed ID: 15150623
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study.
Nardi M; Aloe A; De Marco S; Cognetti F; Iacovelli A; Atlante G; Calabresi F
Am J Clin Oncol; 1997 Jun; 20(3):230-2. PubMed ID: 9167742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
